The FDA will require healthcare providers to tell people if they have dense breast tissue after a mammogram, which indicates a higher risk of developing breast cancer.
Public commenters will kick off Tuesday’s meeting, followed by Covis making its arguments for staying on the market and the FDA and advisory committee members questioning the company.